推荐产品
等級
pharmaceutical primary standard
API 家族
mesalamine, mesalazine
製造商／商標名
EDQM
mp
275-280 °C (dec.) (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI 密鑰
KBOPZPXVLCULAV-UHFFFAOYSA-N
基因資訊
human ... ALOX5(240) , PPARG(5468) , PTGS1(5742) , PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
相關產品
产品编号
说明
价格
訊號詞
Warning
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
No data available
閃點（°C）
No data available
其他客户在看
Morris Gordon et al.
The Cochrane database of systematic reviews, (1)(1), CD008414-CD008414 (2011-01-21)
The use of 5-aminosalicylates (5-ASAs) in Crohn's disease (CD) is controversial. A recent Cochrane review found that 5-ASAs are not effective for the maintenance of medically-induced remission in CD, but their role in the maintenance of surgically-induced remission is unclear.
P Desreumaux et al.
Alimentary pharmacology & therapeutics, 24 Suppl 1, 2-9 (2006-08-31)
The effectiveness of sulfasalazine depends on the splitting of the diazo bond in the molecule by the action of bacteria in the large bowel, releasing the pharmacologically active moiety, 5-aminosalicylic acid. The development of pH-dependent, delayed-release formulations of 5-aminosalicylic acid
Roja Rahimi et al.
Digestive diseases and sciences, 54(4), 712-721 (2008-08-07)
5-Aminosalicylates are the standard treatment for induction and maintenance of remission in mild-to-moderate ulcerative colitis. In recent years, the 5-aminosalicylic acid-containing pro-drug balsalazide has been the focus of attention. To compare the efficacy and tolerance of balsalazide and mesalazine by
Alexander C Ford et al.
The American journal of gastroenterology, 106(12), 2070-2077 (2011-09-07)
Maintenance therapy with 5-aminosalicylates (5-ASAs) is recommended in patients with quiescent ulcerative colitis (UC), but compliance rates are low. Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied
A B Hawthorne et al.
Alimentary pharmacology & therapeutics, 27(12), 1157-1166 (2008-04-04)
Significant number of patients with ulcerative colitis (UC) fail to comply with treatment. To review issues surrounding medication non-adherence in inflammatory bowel disease (IBD), including the clinical and health service implications in the UK, and discuss strategies for optimizing medication
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门